693 related articles for article (PubMed ID: 7534620)
1. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
2. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
3. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
[TBL] [Abstract][Full Text] [Related]
5. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
6. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
7. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
[TBL] [Abstract][Full Text] [Related]
8. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
[TBL] [Abstract][Full Text] [Related]
9. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.
Linsley PS; Nadler SG; Bajorath J; Peach R; Leung HT; Rogers J; Bradshaw J; Stebbins M; Leytze G; Brady W
J Biol Chem; 1995 Jun; 270(25):15417-24. PubMed ID: 7541042
[TBL] [Abstract][Full Text] [Related]
10. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
11. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
12. The interaction properties of costimulatory molecules revisited.
Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
[TBL] [Abstract][Full Text] [Related]
13. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
[TBL] [Abstract][Full Text] [Related]
14. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
15. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
[No Abstract] [Full Text] [Related]
16. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
18. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
[TBL] [Abstract][Full Text] [Related]
19. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).
Morton PA; Fu XT; Stewart JA; Giacoletto KS; White SL; Leysath CE; Evans RJ; Shieh JJ; Karr RW
J Immunol; 1996 Feb; 156(3):1047-54. PubMed ID: 8557978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]